This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Lactobacillus Farciminis and Hyperalgesia

This study has been completed.
Information provided by:
Lallemand SAS Identifier:
First received: February 25, 2009
Last updated: April 30, 2009
Last verified: April 2009
We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.

Condition Intervention Phase
Inflammation Pain Drug: Lactobacillus farciminis Drug: Placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: Effect of a Dialy Consumption of a Probiotic (Lactobacillus Farciminis) on Hyperalgesia in Response to Thermal Stimulation

Resource links provided by NLM:

Further study details as provided by Lallemand SAS:

Primary Outcome Measures:
  • Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus.

Secondary Outcome Measures:
  • Measurement of cutaneous temperature of hyperalgesia areas

Enrollment: 48
Study Start Date: February 2009
Study Completion Date: April 2009
Primary Completion Date: April 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
24 healthy volunteers consuming L.farciminis during three weeks
Drug: Lactobacillus farciminis
1 capsule per day. Each capsule containing 4*109 CFU
Placebo Comparator: 2
24 healthy volunteers consuming placebo during three weeks
Drug: Placebo
1 capsule per day


Ages Eligible for Study:   18 Years to 60 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy volunteers

Exclusion Criteria:

  • consumption of yogurts
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00852865

Cpc / Cic-Inserm 501
Clermont-Ferrand, France, 63000
Sponsors and Collaborators
Lallemand SAS
Principal Investigator: Claude DUBRAY, Professor CPC/CIC-INSERM 501
  More Information

Responsible Party: Henri DURAND, LALLEMAND SAS Identifier: NCT00852865     History of Changes
Other Study ID Numbers: HN 08-17
Study First Received: February 25, 2009
Last Updated: April 30, 2009

Keywords provided by Lallemand SAS:

Additional relevant MeSH terms:
Pathologic Processes
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms processed this record on August 18, 2017